Please provide your email address to receive an email when new articles are posted on . scPharmaceuticals Inc. announced the FDA approved its self-administered subcutaneous furosemide injection for ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

The U.S. Food and Drug Administration has approved Lasix ONYU, an at-home version of the common heart failure drug Lasix The device allows safe treatment for fluid buildup without hospital IV infusion ...

For patients with chronic heart failure (HF) who have persistent congestion despite high doses of oral loop diuretics, the right way to intensify diuretics in the outpatient setting may be narrowed, ...

Loop diuretics, and in particular furosemide, are the most effective agents for the management of signs and symptoms of fluid overload in patients with heart failure (HF). Indeed, through their ...

The US Food and Drug Administration (FDA) has approved a furosemide preparation (Furoscix, scPharmaceuticals) intended for subcutaneous self-administration by outpatients with chronic heart failure ...

CIBA, JAPAN — For acute heart failure (HF) patients arriving in the emergency department (ED), administration of intravenous (IV) furosemide within 1 hour is independently associated with lower ...

The FDA approved the first furosemide (Furoscix) formulation for subcutaneous self-administration by patients with congestive heart failure, scPharmaceuticals announced. The IV-equivalent formulation ...

LEXINGTON, Mass., scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics phase 3 pivotal registration trial. The trial in patients with heart failure ...

HealthDay News — Intravenous (IV) diuretics appear to be safe and effective for outpatient volume management in heart failure, according to a study published online December 2 in JACC: Heart Failure.